<>
Oncoinvent published clinical dosimetry results from Phase 1 studies of Radspherin in the Journal of Nuclear Medicine, showing absorbed radiation doses to normal organs remained well below toxicity thresholds. Conducted at Oslo University Hospital, the findings validate the safety profile of this targeted alpha therapy for peritoneal metastases.
Clinical Dosimetry Data Validates Normal Tissue Safety
In August 2026, biotech firm Oncoinvent announced the peer-reviewed publication of clinical dosimetry data for Radspherin in the Journal of Nuclear Medicine. The data confirms that localized treatment delivers therapeutic payloads to the abdominal cavity while sparing vital organs from excessive radiation.
Quantifying radiation exposure in early-phase clinical trials remains a methodological hurdle, particularly for alpha-emitting isotopes where standard imaging alone cannot calculate precise internal organ doses. To resolve this, researchers at The Norwegian Radium Hospital utilized a hybrid assessment model. By combining targeted imaging with systematic blood sampling and advanced biokinetic modeling, the study mapped radiation distribution accurately across healthy tissues.
In Plain English: The Clinical Takeaway
- Dosimetry: The scientific measurement and calculation of the radiation dose absorbed by body tissues during medical treatments.
- Peritoneal Metastases: Cancer that has spread to the lining of the abdominal cavity, a common and difficult-to-treat complication of gastrointestinal and gynecological malignancies.
- Alpha Radiopharmaceutical: A targeted medical drug carrying radioactive atoms that emit alpha particles, delivering high-energy, short-range cell destruction directly to tumors while minimizing damage to distant healthy tissues.
Overcoming Activity-Limiting Organ Toxicity in Radiotherapy
A primary bottleneck in systemic and cavity-directed radiopharmaceuticals is unintended exposure to activity-limiting organs, most notably the kidneys and red bone marrow. When these tissues absorb excess radiation, patients face severe hematological toxicities or renal impairment, capping the maximum therapeutic dose clinicians can administer. The newly published findings indicate that Radspherin bypasses this limitation. Absorbed doses to the kidneys and bone marrow stayed well below established safety thresholds, reinforcing the favorable safety profile observed across initial clinical evaluations.
Regulatory Context and Development Pathways in Europe and Beyond
The publication marks a significant regulatory and scientific milestone as Oncoinvent advances Radspherin through clinical pipelines.
| Parameter | Clinical Observation |
|---|---|
| Target Indication | Peritoneal metastases from ovarian and colorectal cancer |
| Study Cohort Size | 9 patients evaluated in dosimetry cohorts |
| Key Evaluated Organs | Kidneys, red bone marrow, and surrounding normal abdominal tissues |
| Primary Dosimetric Finding | Absorbed doses remained well below established toxicity limits |
Kari Myren, Chief Medical Officer at Oncoinvent, emphasizes the broader impact of the publication.
References
- Journal of Nuclear Medicine – Normal Tissue Dosimetry of Intraperitoneal Radium-224-Microparticle Therapy
Disclaimer: This article is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
>
